United Therapeutics (NASDAQ:UTHR) CEO Sells $5,481,215.00 in Stock

Key Points

• CEO Martine Rothblatt sold 9,500 shares on May 4 at an average price of $576.97 for a total of $5,481,215, leaving her with 40,513 shares (a 19% reduction in her position).
• United Therapeutics shares traded down about 1.6% to $572.20 on above-average volume; the company has a market cap of $25.08 billion and a P/E of 20.51 with a 12‑month high of $607.89.
• The company reported quarterly EPS of $7.70 (beating estimates by $0.92) but revenue of $790.2M missed consensus, and analysts maintain a consensus rating of "Moderate Buy" with a $601.50 price target.

United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $576.97, for a total transaction of $5,481,215.00. Following the completion of the sale, the chief executive officer owned 40,513 shares of the company's stock, valued at $23,374,785.61. This trade represents a 19.00% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

United Therapeutics Stock Down 1.6%

NASDAQ:UTHR traded down $9.02 during trading hours on Tuesday, reaching $572.20. 560,802 shares of the stock were exchanged, compared to its average volume of 478,626. United Therapeutics Corporation has a twelve month low of $272.12 and a twelve month high of $607.89. The business has a 50-day moving average of $543.83 and a two-hundred day moving average of $498.27. The company has a market capitalization of $25.08 billion, a price-to-earnings ratio of 20.51, a PEG ratio of 1.62 and a beta of 0.60.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.78 by $0.92. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The firm had revenue of $790.20 million for the quarter, compared to the consensus estimate of $814.80 million. During the same quarter in the previous year, the business earned $6.19 EPS. The company's quarterly revenue was up 7.4% compared to the same quarter last year. On average, research analysts forecast that United Therapeutics Corporation will post 27.97 EPS for the current fiscal year.

Hedge Funds Weigh In On United Therapeutics

Institutional investors have recently modified their holdings of the business. AE Wealth Management LLC boosted its holdings in United Therapeutics by 396.3% in the 3rd quarter. AE Wealth Management LLC now owns 4,288 shares of the biotechnology company's stock valued at $1,798,000 after purchasing an additional 3,424 shares in the last quarter. Great Lakes Advisors LLC raised its stake in shares of United Therapeutics by 194.7% during the 3rd quarter. Great Lakes Advisors LLC now owns 4,503 shares of the biotechnology company's stock worth $1,888,000 after buying an additional 2,975 shares in the last quarter. Optimize Financial Inc acquired a new stake in shares of United Therapeutics in the 3rd quarter valued at approximately $444,000. Tobam lifted its holdings in shares of United Therapeutics by 183.9% in the 3rd quarter. Tobam now owns 7,646 shares of the biotechnology company's stock valued at $3,205,000 after buying an additional 4,953 shares during the period. Finally, Sawgrass Asset Management LLC purchased a new stake in shares of United Therapeutics in the third quarter valued at approximately $11,460,000. 94.08% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms recently commented on UTHR. HC Wainwright boosted their target price on United Therapeutics from $600.00 to $660.00 and gave the stock a "buy" rating in a research note on Tuesday, March 31st. Oppenheimer lifted their price target on shares of United Therapeutics from $575.00 to $600.00 and gave the stock an "outperform" rating in a research note on Thursday, February 26th. Bank of America boosted their price target on shares of United Therapeutics from $569.00 to $626.00 and gave the company a "neutral" rating in a research report on Tuesday, March 31st. Jefferies Financial Group restated a "buy" rating on shares of United Therapeutics in a research note on Monday, March 2nd. Finally, UBS Group lifted their target price on United Therapeutics from $655.00 to $705.00 and gave the stock a "buy" rating in a research report on Thursday, March 5th. Ten investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $601.50.

About United Therapeutics

United Therapeutics Corporation NASDAQ: UTHR is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.